553 related articles for article (PubMed ID: 25432172)
1. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.
Crompton JG; Sukumar M; Roychoudhuri R; Clever D; Gros A; Eil RL; Tran E; Hanada K; Yu Z; Palmer DC; Kerkar SP; Michalek RD; Upham T; Leonardi A; Acquavella N; Wang E; Marincola FM; Gattinoni L; Muranski P; Sundrud MS; Klebanoff CA; Rosenberg SA; Fearon DT; Restifo NP
Cancer Res; 2015 Jan; 75(2):296-305. PubMed ID: 25432172
[TBL] [Abstract][Full Text] [Related]
2. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
4. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
6. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Shrimali RK; Yu Z; Theoret MR; Chinnasamy D; Restifo NP; Rosenberg SA
Cancer Res; 2010 Aug; 70(15):6171-80. PubMed ID: 20631075
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
10. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L
Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998
[TBL] [Abstract][Full Text] [Related]
11. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
Ma D; Niederkorn JY
Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
[TBL] [Abstract][Full Text] [Related]
14. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
16. Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
Considine B; Hurwitz ME
Methods Mol Biol; 2020; 2097():309-327. PubMed ID: 31776935
[TBL] [Abstract][Full Text] [Related]
17. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.
van der Waart AB; van de Weem NM; Maas F; Kramer CS; Kester MG; Falkenburg JH; Schaap N; Jansen JH; van der Voort R; Gattinoni L; Hobo W; Dolstra H
Blood; 2014 Nov; 124(23):3490-500. PubMed ID: 25336630
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
Santos JM; Havunen R; Siurala M; Cervera-Carrascon V; Tähtinen S; Sorsa S; Anttila M; Karell P; Kanerva A; Hemminki A
Int J Cancer; 2017 Oct; 141(7):1458-1468. PubMed ID: 28614908
[TBL] [Abstract][Full Text] [Related]
20. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
